AMBS needs a Big Pharma endorsement (i.e., Novartis) to capture the market's attention. I suspect a lot of shareholders were disappointed (again) when there was no announcement on the BD specificity ratings or a BD JV Agreement - doesn't mean to say that these initiatives aren't being worked on - we simply don't know...yet.
News 
Market Data 
Discover 
